Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Abstract Text:

Tamer A Elbayoumi,Vladimir P Torchilin,

PURPOSE: To further improve tumour targeting and delivery of imaging agents by long-circulating liposomes via the coupling of the anti-cancer monoclonal antibody 2C5 with nucleosome-restricted activity, which can recognize the surface of various tumours but not normal cells and can specifically target pharmaceutical carriers to tumour cells in vitro and in vivo. METHODS: The 2C5 antibody was attached to the surface of long-circulating PEG-liposomes (LCL) by the post-insertion technique after antibody modification with a single-terminus activated PEG-lipid derivative to yield nucleosome-specific tumour-targeted liposomes. Tumour cell binding of the targeted liposomes was verified both by fluorescence microscopy and by flow cytometry in several cell lines using fluorescently labelled liposomes. 111In-radiolabelled liposomal formulations (prepared using membrane-anchored chelating groups) were used to examine in vivo biodistribution and tumour accumulation of liposomes by direct gamma scintigraphy. RESULTS: The 2C5 antibody-modified LCL demonstrated a three- to eightfold increase in in vitro specific cell binding to various cancer cell lines of diverse origin. 111In-labelled tumour-targeted liposomes demonstrated prolonged circulation and doubled tumour accumulation compared with that of control formulations. Whole-body gamma scintigraphic imaging of mice implanted with different tumours revealed markedly faster (6 h post injection for 2C5-LCL vs 24 h for non-specific analogues) and superior in vivo tumour visualization with 111In-2C5-LCL than with the 2C5-free formulations in tested tumour models. CONCLUSION: The 2C5 antibody-modified LCL effectively and specifically accumulate in various tumours and can serve as delivery vehicles for imaging agents, allowing for fast and efficient tumour visualization.

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Publishing Authors By Initials

TA Elbayoumi,VP Torchilin,

For similar biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics: tissue distribution research abstracts see: biochemical phenomena, metabolism, and nutrition: metabolism: pharmacokinetics: tissue distribution research

PUBMED ID PMID:

MEDLINE DATE:

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: European journal of nuclear medicine and molecular

VOLUME: 33

Page Numbers: 1196-205

Journal Abbreviation: Eur. J. Nucl. Med. Mol. Imagin

ISSN: 1619-7070

DAY: 9

MONTH: 06

YEAR: 2006

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101140988

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Keywords Mesh Terms:

KEYWORDS: Tissue Distribution

MESH TERMS: radionuclide imaging

Chemical & Substance for Abstract: Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Information

Substance Name: Nucleosomes

Registry Number: 0

Grant and Affiliation Information for Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.

AFFILIATION: Department of Pharmaceutical Sciences, Northeastern University, Mugar Building, Room 312, 360 Huntington Avenue, Boston, MA 02115, USA.

Country: Germany

AGENCY: United States NIBIB

GRANT: R01-EB02995

ACRONYM: EB

MEDLINETA: Eur J Nucl Med Mol Imaging

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies Related Publications

• "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers.
• "Smart" Drug Carriers: PEGylated TATp-Modified pH-Sensitive Liposomes.
• Antibody-modified liposomes for cancer chemotherapy.
• Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
• Bioengineering and Imaging Research Opportunities Workshop V: A summary on Imaging and Characterizing Structure and Function in Native and Engineered Tissues.
• Bioengineering and Imaging Research Opportunities Workshop V: a white paper on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop V: summary of findings on imaging and characterizing structure and function in native and engineered tissues.
• Bioengineering and imaging research opportunities workshop v: a summary.
• Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates.
• Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies.
• Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
• Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes.
• Enhanced tumor visualization by gamma-scintigraphy with 111In-labeled polychelating-polymer-containing immunoliposomes.
• Mitochondriotropic cationic vesicles: a strategy towards mitochondrial gene therapy.
• Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: Improved drug solubilization and enhanced in vitro cytotoxicity.
• Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
• Nanocarriers.
• PEGylated dextran as long-circulating pharmaceutical carrier.
• Photodynamic therapy of experimental B-16 melanoma in mice with tumor-targeted 5,10,15,20-tetraphenylporphin-loaded PEG-PE micelles.
• Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux.
• Polymeric contrast agents for medical imaging.
• Preface. Fifth International Nanomedicine and Drug Delivery Symposium (NanoDDS'07).
• Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.
• Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology.
• Surface Modification of Pharmaceutical Nanocarriers with Ascorbate Residues Improves their Tumor-Cell Association and Killing and the Cytotoxic Action of Encapsulated Paclitaxel In Vitro.
• TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice.
• Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers.
• Tatp-mediated intracellular delivery of pharmaceutical nanocarriers.
• The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells.
• Tumor-specific antibody-mediated targeted delivery of Doxil((R)) reduces the manifestation of auricular erythema side effect in mice.